Skip to main content
Log in

In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera

  • Original Articles
  • Pt Complexes, In vivo Distribution
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The in vivo distribution in man of the four platinum derivatives cis-dichlorodiammine platinum(II) (DDP), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV) (CHIP), cis-dichloro-bis-cyclopropylamine platinum (II) (CP), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) (CBDCA) has been observed. The availability of these compounds labelled with the radioactive isotope of platinum, platinum-191, has made serial in vivo imaging of their distribution possible.

Injection of 17–35 MBq (5–28 mg) of the labelled compound IV was followed by imaging, using a gamma camera, with particular reference to the kidneys, liver, and tumour site.

Hepatic and renal clearances were observed in all nine patients, but no unequivocal evidence of tumour uptake was found. The left kidney uptake was estimated at times up to 7 days after injection. Mathematical analysis of some of the uptake curves failed to show any significant difference between the clearance times observed. However, the two patients who received CBDCA did show a higher initial renal uptake, falling within the 1st day to levels comparable with those of the other compounds, and the three patients who received DDP showed consistently liver uptake.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Einhorn LH, Williams SD (1979) The role of cis-platinum in solid-tumour, therapy. N Engl J Med 300:289–291

    Google Scholar 

  2. Harrison H, McAuliffe CA, Zaki A, Baer J, Sharma H, Smith A, Jackson H, Fox BW (1983) A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), and cis-dichloro-bis-cyclopropylamine platinum (II) Cancer Chemother Pharmacol 10:90–95

    Google Scholar 

  3. Kidani Y, Inagaki K, Saito R, Tsukagoshi S (1977) Synthesis and anti-tumour activities of platinum (II) complexes of 1,2-diamminocyclohexane isomers and their related derivatives. J Clin Haematol Oncol 7:197–209

    Google Scholar 

  4. Lange RC, Spencer RP, Harder HC (1973) The antitumour agent cis-Pt(NH3)2Cl2: Distribution studies and dose calculation for 193mPt and 195mPt. J Nucl Med 14:191–195

    Google Scholar 

  5. Prestayko AW, D'Aoust JC, Issell BF, Cooke ST (1979) cis-Platin (cis-diammine dichloroplatinum II). Cancer Treat Rev 6:17–39

    Google Scholar 

  6. Sharma H, Smith AG (1981) The short-lived radioisotope production programme at Manchester. J Radioanal Chem 64:249–255

    Google Scholar 

  7. Sharma H, Thatcher N, Baer J, Zaki A, McAuliffe CA, Growther D, Owens S, Fox BW (1983) Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) (CBDCA) in cancer patients. Cancer Chemother Pharmacol 11:5–7

    Google Scholar 

  8. Smith PHS, Taylor DM (1974) Distribution and retention of the antitumour agent 195mPt-cis-dichlorodiammine platinum(II) in man. J Nucl Med 15:349–351

    Google Scholar 

  9. Speer RJ, Ridgway H, Stewart DP, Hall LM, Zapata A, Hill JM (1977) Sulfato-1,2-diamincyclohexane platinum (II): A potential new antitumour agent. J Clin Haematol Oncol 7:210–219

    Google Scholar 

  10. Thatcher N, Sharma H, Harrison R, Smith A, Zaki A, McAuliffe CA, Fox BW, Crowther D (1982) Blood clearance of three radioactively labelled platinum complexes, cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV) and cis-dichloro-bis-cyclopropylamine platinum(II) in patients with malignant disease. Cancer Chemother Pharmacol 9:13–16

    Google Scholar 

  11. Tobe ML, Khokhar AR (1977) Structure, activity, reactivity and solubility relationships of platinum diamine complexes. J Clin Haematol Oncol 7:114–137

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Owens, S.E., Thatcher, N., Sharma, H. et al. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera. Cancer Chemother. Pharmacol. 14, 253–257 (1985). https://doi.org/10.1007/BF00258128

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00258128

Keywords

Navigation